ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society

(2018) Erik Thunnissen et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Next-Generation Sequencing of Lung Cancers

(2017) Siddhartha Devarakonda et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis

(2017) Humberto E Trejo Bittar et al.   HISTOPATHOLOGY

Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement

(2017) Naoki Nakajima et al.   HISTOPATHOLOGY

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

(2017) Dong-Wan Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study

(2017) Ulrike Koitzsch et al.   JOURNAL OF CLINICAL PATHOLOGY

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib

(2017) Trish Thorne-Nuzzo et al.   Journal of Thoracic Oncology

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH

(2017) Johannes M. Heuckmann et al.   Journal of Thoracic Oncology

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

(2017) Wenbin Li et al.   Journal of Thoracic Oncology

ALK-Rearranged Squamous Cell Carcinoma of the Lung Treated with Two Lines of ALK Inhibitors

(2017) Elena Bolzacchini et al.   Journal of Thoracic Oncology

Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer

(2017) Anna Belilovski Rozenblum et al.   Journal of Thoracic Oncology

ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?

(2017) M. von Laffert et al.   LUNG CANCER

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

(2017) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

ALK alterations and inhibition in lung cancer

(2017) Tri Le et al.   SEMINARS IN CANCER BIOLOGY

Drug resistance in ALK-positiveNon-small cell lungcancer patients

(2017) Mengjia Qian et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Optimized immunohistochemistry using the D5F3 antibody provides a reliable test for identification of ALK-positive lung adenocarcinomas

(2017) Gian Luca Rampioni Vinciguerra et al.   VIRCHOWS ARCHIV

Targeting ALK: Precision Medicine Takes on Drug Resistance

(2017) Jessica J. Lin et al.   Cancer Discovery

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

(2017) Mariacarmela Santarpia et al.   Drug Design Development and Therapy

Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis

(2017) Xia Zhang et al.   Oncotarget

Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology

(2017) Adriane F. Evangelista et al.   BMC Pulmonary Medicine

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

(2017) Hélène Roussel et al.   OncoImmunology

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer

(2017) Toni-Maree Rogers et al.   Scientific Reports

Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors

(2016) Rashmi S. Goswami et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Improving Selection Criteria for ALK Inhibitor Therapy in Non–Small Cell Lung Cancer

(2016) Long Jiang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?

(2016) K. M. Kerr et al.   ANNALS OF ONCOLOGY

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK -rearranged non–small cell lung cancer

(2016) C.G. Woo et al.   ANNALS OF ONCOLOGY

Crizotinib resistance: implications for therapeutic strategies

(2016) I. Dagogo-Jack et al.   ANNALS OF ONCOLOGY

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience

(2016) Dara L. Aisner et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib

(2016) E. Larkins et al.   CLINICAL CANCER RESEARCH

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature

(2016) A.J. van der -->Wekken et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer

(2016) J. Zhong et al.   CYTOPATHOLOGY

The (Con-) Fusion in ALK Diagnostics: When Food and Drug Administration–Approved Algorithms Fail

(2016) Jessica Jürgens et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

(2016) Tatsuya Yoshida et al.   JOURNAL OF CLINICAL ONCOLOGY

Reliability Assurance of Detection of EML4-ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China

(2016) Yulong Li et al.   Journal of Thoracic Oncology

Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues

(2016) Kuniko Sunami et al.   Journal of Thoracic Oncology

ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen

(2016) Merdol Ibrahim et al.   Journal of Thoracic Oncology

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

(2016) Antonio Marchetti et al.   Journal of Thoracic Oncology

Routine molecular profiling of patients with NSCLC

(2016) Verena Schildgen et al.   LANCET

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease

(2016) Crispin T Hiley et al.   LANCET

ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare

(2016) Weijie Zhao et al.   LUNG CANCER

Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study

(2016) Qiushi Wang et al.   LUNG CANCER

Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma

(2016) A. Rosoux et al.   LUNG CANCER

Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays

(2016) Antonio Marchetti et al.   LUNG CANCER

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

(2016) Ibiayi Dagogo-Jack et al.   ONCOLOGIST

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

(2016) Siraj M. Ali et al.   ONCOLOGIST

Epidemiology of driver mutations in lung cancer in a German tertiary hospital in patients with testing indication

(2016) Verena Schildgen et al.   Personalized Medicine

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma

(2016) Sanja Dacic et al.   Oncotarget

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

(2016) Boram Lee et al.   Oncotarget

Expanding opportunities for crizotinib resistance in ALK-positive lung cancer patients

(2016) Marius Ilié et al.   Translational Cancer Research

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

Reply to the letter to the editor ‘ALKFISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerningALKstatus screening in lung cancer’ by Uguen et al.

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer

(2015) A. Uguen et al.   ANNALS OF ONCOLOGY

External quality assessment for immunohistochemistry: experiences from NordiQC

(2015) S Nielsen   BIOTECHNIC & HISTOCHEMISTRY

Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

(2015) Hideko Isozaki et al.   CANCER RESEARCH

FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

(2015) S. Khozin et al.   CLINICAL CANCER RESEARCH

French multicentric validation ofALKrearrangement diagnostic in 547 lung adenocarcinomas

(2015) Sylvie Lantuejoul et al.   EUROPEAN RESPIRATORY JOURNAL

EquivocalALKfluorescencein-situhybridization (FISH) cases may benefit from ancillaryALKFISH probe testing

(2015) Christina Selinger et al.   HISTOPATHOLOGY

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision Samples

(2015) Hideyuki Abe et al.   Journal of Thoracic Oncology

Clinical Implications of Variant ALK FISH Rearrangement Patterns

(2015) Xin Gao et al.   Journal of Thoracic Oncology

ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice

(2015) Vittoria Martin et al.   Journal of Thoracic Oncology

A Novel, Highly Sensitive ALK Antibody 1A4 Facilitates Effective Screening for ALK Rearrangements in Lung Adenocarcinomas by Standard Immunohistochemistry

(2015) Kim Gruber et al.   Journal of Thoracic Oncology

ALK FISH and IHC: You Cannot Have One without the Other

(2015) Yasushi Yatabe   Journal of Thoracic Oncology

ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making

(2015) Maximilian von Laffert et al.   LUNG CANCER

Alternative transcription initiation leads to expression of a novel ALK isoform in cancer

(2015) Thomas Wiesner et al.   NATURE

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer

(2015) M. Pekar-Zlotin et al.   ONCOLOGIST

Sense and nonsense in the process of accreditation of a pathology laboratory

(2015) Elodie Long-Mira et al.   VIRCHOWS ARCHIV

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR

(2015) Sang Yun Ha et al.   Oncotarget

Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies

(2015) Hui Chen et al.   Cancers

Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges

(2015) Rajyalakshmi Luthra et al.   Cancers

Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated withALK‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies

(2014) M. I. Ilie et al.   ANNALS OF ONCOLOGY

ALKRearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment

(2014) Greta Alì et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Clinical next-generation sequencing in patients with non-small cell lung cancer

(2014) Ian S. Hagemann et al.   CANCER

Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: Comparison with histological assessment

(2014) Agnese Proietti et al.   CANCER CYTOPATHOLOGY

Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement

(2014) Ling Shan et al.   Diagnostic Pathology

Immunohistochemistry as a screening tool forALKrearrangement in NSCLC: evaluation of five different ALK antibody clones andALKFISH

(2014) Georg Hutarew et al.   HISTOPATHOLOGY

Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review)

(2014) MASSIMO DI MAIO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

A rare case of anEML4-ALK-rearranged lung adenocarcinoma missed by in situ-hybridisation but detected by RT-PCR

(2014) A Roth et al.   JOURNAL OF CLINICAL PATHOLOGY

Detection of Gene Rearrangements in Targeted Clinical Next-Generation Sequencing

(2014) Haley J. Abel et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer

(2014) Maruja E. Lira et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material

(2014) Eugen C. Minca et al.   Journal of Thoracic Oncology

ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme

(2014) Antonio Marchetti et al.   Journal of Thoracic Oncology

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients

(2014) Joana Vidal et al.   Journal of Thoracic Oncology

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators

(2014) Murry W. Wynes et al.   Journal of Thoracic Oncology

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances

(2014) Florian Cabillic et al.   Journal of Thoracic Oncology

Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer

(2014) Michelle Houang et al.   PATHOLOGY

The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization

(2014) Lien Tembuyser et al.   PLoS One

A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population

(2014) Shaodong Hong et al.   Scientific Reports

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma

(2013) J. Ying et al.   ANNALS OF ONCOLOGY

The use of stained cytologic direct smears forALKgene rearrangement analysis of lung adenocarcinoma

(2013) Bryan L. Betz et al.   CANCER CYTOPATHOLOGY

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

ALK Status Testing in Non–Small Cell Lung Carcinoma

(2013) Eugen C. Minca et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   Journal of Thoracic Oncology

Optimal Detection of ALK Rearranged Lung Adenocarcinomas

(2013) Niki Karachaliou et al.   Journal of Thoracic Oncology

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays

(2013) Tianhong Li et al.   Journal of Thoracic Oncology

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations

(2013) Doraid Alrifai et al.   LUNG CANCER

Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung

(2013) Hans-Ulrich Schildhaus et al.   MODERN PATHOLOGY

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

(2013) Pablo Martinez et al.   PLoS One

Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases

(2012) Hyojin Kim et al.   HISTOPATHOLOGY

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer

(2012) Nir Peled et al.   Journal of Thoracic Oncology

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

(2012) Chris M.J. Conklin et al.   Journal of Thoracic Oncology

ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma

(2012) Sanjay Popat et al.   LUNG CANCER

Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene?

(2012) Nobuaki Ochi et al.   LUNG CANCER

Epidemiology of EML4–ALK translocations in a small, German non-small-cell lung cancer patient cohort

(2012) Verena Schildgen et al.   Personalized Medicine

Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance

(2012) C. M. Lovly et al.   Science Translational Medicine

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma

(2011) P. Hofman et al.   ANNALS OF ONCOLOGY

RNAscope

(2011) Fay Wang et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression

(2011) Hyojin Kim et al.   Journal of Thoracic Oncology

Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma

(2011) Ping Yang et al.   Journal of Thoracic Oncology

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study

(2011) Anne McLeer-Florin et al.   Journal of Thoracic Oncology

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

(2010) M. Mino-Kenudson et al.   CLINICAL CANCER RESEARCH

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues

(2009) Maria Paola Martelli et al.   AMERICAN JOURNAL OF PATHOLOGY

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

(2009) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

(2008) Kentaro Inamura et al.   Journal of Thoracic Oncology

Direct multiplexed measurement of gene expression with color-coded probe pairs

(2008) Gary K Geiss et al.   NATURE BIOTECHNOLOGY